|
Synonyms: ACTIMAB® | HuM195 | SGN-33 | SMART M195
Compound class:
Antibody
Comment: Lintuzumab is a monoclonal antibody directed against CD33, a surface antigen found on myeloid leukemia cells. A modified version of lintuzumab that is conjugated with the chelator satetraxetan to facilitate actinium (225Ac) radiolabelling (a radioimmunotherapeutic) has been developed (see Patent US6670456 [4] and IMGT/mAb-db ID 936). 225Ac emits α particles and is used as these cause less nonspecific cytotoxicity than β particles (i.e. decreased killing of bystander cells). 225Ac has been termed a 'nano-generator' as for each decay producing a high-energy α particle, a series of daughter atoms generate additional α particles, effectively amplifying the radioactive dose at the target site. Lintuzumab is a humanized version of the murine anti-CD33 antibody, M195 [2].
Ligand Activity Visualisation ChartsThese are box plot that provide a unique visualisation, summarising all the activity data for a ligand taken from ChEMBL and GtoPdb across multiple targets and species. Click on a plot to see the median, interquartile range, low and high data points. A value of zero indicates that no data are available. A separate chart is created for each target, and where possible the algorithm tries to merge ChEMBL and GtoPdb targets by matching them on name and UniProt accession, for each available species. However, please note that inconsistency in naming of targets may lead to data for the same target being reported across multiple charts. ✖ |
| References |
|
1. Actinium Pharmaceuticals Inc.
Actimab-A. Accessed on 24/11/2014. Modified on 24/11/2014. http://www.actiniumpharma.com, http://www.actiniumpharma.com/products/pipeline/actimab-a/ |
|
2. Caron PC, Co MS, Bull MK, Avdalovic NM, Queen C, Scheinberg DA. (1992)
Biological and immunological features of humanized M195 (anti-CD33) monoclonal antibodies. Cancer Res, 52 (24): 6761-7. [PMID:1458463] |
|
3. Ferlazzo G, Spaggiari GM, Semino C, Melioli G, Moretta L. (2000)
Engagement of CD33 surface molecules prevents the generation of dendritic cells from both monocytes and CD34+ myeloid precursors. Eur J Immunol, 30 (3): 827-33. [PMID:10741398] |
|
4. Frank RK, Kiefer GE, Simon J. (2003)
Actinium-225 complexes and conjugates for targeted radiotherapy. Patent number: US6670456. Assignee: Dow Global Technologies Inc.. Priority date: 28/02/2001. Publication date: 30/12/2003. |
|
5. Garnache-Ottou F, Chaperot L, Biichle S, Ferrand C, Remy-Martin JP, Deconinck E, de Tailly PD, Bulabois B, Poulet J, Kuhlein E et al.. (2005)
Expression of the myeloid-associated marker CD33 is not an exclusive factor for leukemic plasmacytoid dendritic cells. Blood, 105 (3): 1256-64. [PMID:15388576] |
|
6. Paul SP, Taylor LS, Stansbury EK, McVicar DW. (2000)
Myeloid specific human CD33 is an inhibitory receptor with differential ITIM function in recruiting the phosphatases SHP-1 and SHP-2. Blood, 96 (2): 483-90. [PMID:10887109] |
|
7. Taylor VC, Buckley CD, Douglas M, Cody AJ, Simmons DL, Freeman SD. (1999)
The myeloid-specific sialic acid-binding receptor, CD33, associates with the protein-tyrosine phosphatases, SHP-1 and SHP-2. J Biol Chem, 274 (17): 11505-12. [PMID:10206955] |
|
8. Ulyanova T, Blasioli J, Woodford-Thomas TA, Thomas ML. (1999)
The sialoadhesin CD33 is a myeloid-specific inhibitory receptor. Eur J Immunol, 29 (11): 3440-9. [PMID:10556798] |
